Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Kidney cancer at ESMO 2022: KEYNOTE-564 and PROSPER

Ramaprasad Srinivasan, MD, PhD, National Cancer Institute, Bethesda, MD, talks on his highlights in kidney cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress, including findings from the Phase III KEYNOTE-564 (NCT03142334), which assessed adjuvant pembrolizumab in renal cell carcinoma (RCC), as well as results from the Phase III PROSPER trial (NCT03055013) of perioperative nivolumab in RCC. Dr Srinivasan additionally discusses the use of telisotuzumab in RCC. This interview took place at the ESMO 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.